Phenylalanine-free protein substitute in tablet form (xphe minis) (DrugBank: Phenylalanine)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 0 |
| 240 | Phenylketonuria | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04375592 (ClinicalTrials.gov) | October 2020 | 21/4/2020 | Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of Phenylketonuria | XPhe Minis - Acceptability and Tolerance Market Research | Phenylketonurias;Hyperphenylalaninaemia;Tetrahydrobiopterin Deficiency | Dietary Supplement: Phenylalanine-free protein substitute in tablet form (XPhe minis) | metaX Institut fuer Diatetik GmbH | Birmingham Children's Hospital | Not yet recruiting | 7 Years | 18 Years | All | 10 | NULL |